Blogs about: Mdv3100
Featured Blog
ASCO commentary and update no. 1
On Saturday there were two major prostate cancer sessions and additional poster sessions that included prostate cancer-related material at the annual meeting of the American Society for Clinical Oncol… more →
THE "NEW" PROSTATE CANCER INFOLINK
ASCO commentary and update no. 1
Sitemaster wrote 1 month ago: On Saturday there were two major prostate cancer sessions and additional poster sessions that includ … more →
Can SmallCap Prostate Cancer Firms Borrow Some of Dendreon’s Spotlight?
AllenCaron wrote 3 months ago: Forty-eight hours ago, the market cap of Dendreon, (Nasdaq:DNDN) www.dendreon.com, fell squarely wit … more →
Two compounds effective in treating resistant advanced prostate cancer
— 1 comment
Jim Tucker wrote 3 months ago: MODERN MEDICINE: TWO compounds – the diarylthiohydantoins RD162 and MDV3100 – are effect … more →
An MDV3100 update
Sitemaster wrote 3 months ago: There are several stories on the Web today about a forthcoming article in Science giving data about … more →
The Thursday news reports: March 19, 2009
Sitemaster wrote 4 months ago: There are six new reports in today’s news, of which the most immediately important would seem … more →
More from the GU Oncology Symposium -- a wrap-up
Sitemaster wrote 4 months ago: Looking through my assorted notes from the meeting this morning after getting home late last night, … more →
In Friday's research news: December 19, 2008
Sitemaster wrote 7 months ago: In the prostate cancer research news today, there are two new developments and a report of another f … more →
MDV3100 in castration-resistant prostate cancer
— 3 comments
Sitemaster wrote 8 months ago: Medscape has just published an extensive update on the ongoing Phase I/II clinical trial of MDV3100 … more →
Medivation's androgen receptor antagonist MDV3100 effective in prostate cancer
crimsoncanary wrote 1 year ago: Phase I/II data presented at ASCO show Medivation’s androgen receptor antagonist MDV3100 to de … more →
Have your say. Start a blog.
See our free features →
An 
Joint
